PTK2 and cancer: For example, Defactinib has been tested in phase II trials for ovarian cancer but showed only moderate improvements in patient survival rates, partly because of resistance development over time or its inability to block FAK’s scaffolding roles, which are important for cancer progression without involving phosphorylation14.